Mobile website
Recombinant fibronectin polypeptide CH50 improves positive immune regulation in tumor microenvironment
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To investigate the inhibitory effect of in vivo non-targeting transfection of recombinant fibronectin polypeptide CH50 against tumors and to study the related mechanisms. Methods: After inoculated with tumor cells, BALB/c mice were injected with CH50 plasmids, control plasmids, and normal saline separately. The growth of the tumor was observed; the expression of genes (such as B7-1, B7-H1 etc.) in tumor tissues was detected by RT-PCR; and the count of T lymphocytes in local tumor tissues was analyzed by flow cytometry. Results: The tumor growth was obviously suppressed by in vivo CH50 expression. The expression of genes (B7-1 and B7-H1) was up-regulated along with the growth of tumor. CH50 increased the ratios of B7-1/B7-H1 and B7-1/B7-DC and suppressed the up-regulation of IL-10 and TGF-β genes. The direct action of CH50 on H22 cells resulted in the down-regulatoin of TGF-β gene. The count of T lymphocytes in tumor tissues of CH50 treatment group was significantly higher than that in other groups. Conclusion: Expression of CH50 by non-targeting transfection can effectively inhibit the growth of tumor; the regulation of the immuno-regulatory genes in tumor microenvironment is an important part of the treatment mechanism of CH50.
Keywords:
Project Supported:
Clc Number:
